title: Insulin-like growth factor I is expressed in classical and nodular lymphocyte-predominant Hodgkin's lymphoma tumour and microenvironmental cells.
abstract: Hodgkin's lymphoma (HL) is among the most frequent nodal lymphomas in the Western world and is classified into two disease entities: nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) and classical Hodgkin's lymphoma (cHL, 95% of all HL). HL lesions are characterised by a minority of clonal neoplastic cells, namely Hodgkin and Reed-Sternberg (HRS) cells and their variants in cHL and lymphocyte-predominant (LP) cells in NLPHL, both occurring within a microenvironment of, for example, reactive T and B cells, macrophages and granulocytes that are assumed to support the proliferation and maintenance of neoplastic cells through cytokines, chemokines and growth factors. Insulin-like growth factor I (IGF-I) is an important growth factor involved in proliferation, differentiation, apoptosis and cell survival of numerous (including immune) tissues and probably has a role in tumour pathogenesis and maintenance. Although HL is characterised by disturbed cell differentiation and apoptosis mechanisms, with the involvement of the IGF-I receptor (IGF-1R), the distinct location of IGF-I in HL has not yet been defined. We localise IGF-I by double-immunofluorescence in frequent neoplastic cells of all cHL and NLPHL cases investigated. Additionally, IGF-I immunoreactivity is detected in high endothelial venules and various immune cells within the surrounding tissue of cHL including neutrophils and macrophages. IGF-1R immunoreactivity of variable intensity is found in HRS cells and high endothelial venules within the microenvironment in cHL. We assume that autocrine and paracrine IGF-I plays an anti-apoptotic role in tumour pathogenesis and in shaping the tumour microenvironment.
authors.affiliation: Research Group Neuro-endocrine-immune Interactions, Institute of Anatomy, University of Zurich, Zurich, Switzerland, elisabeth.eppler@uzh.ch.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Eppler
authors.forename: Eva
authors.initials: E
authors.lastname: Janas
authors.forename: Karl
authors.initials: K
authors.lastname: Link
authors.forename: Lukas
authors.initials: L
authors.lastname: Weidmann
authors.forename: Helena
authors.initials: H
authors.lastname: Bischofberger
authors.forename: Michael
authors.initials: M
authors.lastname: Wenger
authors.forename: Marianne
authors.initials: M
authors.lastname: Tinguely
authors.forename: Peter
authors.initials: P
authors.lastname: Schraml
authors.forename: Holger
authors.initials: H
authors.lastname: Moch
authors.forename: Christian
authors.initials: C
authors.lastname: Fellbaum
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006689:Hodgkin Disease / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D016256:Lewis X Antigen / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012598:Sclerosis; D059016:Tumor Microenvironment; D055815:Young Adult
chemical_list: D016256:Lewis X Antigen; D007334:Insulin-Like Growth Factor I